Corcept's Relacorilant Rejection: Stock Plummets
Update: 2026-01-02
Description
Corcept Therapeutics stock plummets 70% after FDA rejects relacorilant for Cushings syndrome, halting growth plans and opening the door for rival Xeris Biopharmas Recorlev to capture a larger market share. Checkout Solipillow.com
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
